Abdullah Kadir DOLU, Ahmet Anıl BAŞKURT, Yusuf DEMİR, Oktay ŞENÖZ
Meandros Medical and Dental Journal - 2026;27(1):108-115
Objective: This study aimed to evaluate the prognostic value of the Controlling Nutritional Status (CONUT) score for predicting 1-year major adverse cardiovascular events (MACE) in patients hospitalized for acute coronary syndrome (ACS) and treated with the potent P2Y?? inhibitor ticagrelor. Materials and Methods: A total of 817 consecutive ACS patients admitted between September 2024 and July 2025 were prospectively enrolled. Patients with advanced malignancy, active infection, end-stage liver disease, or receiving other P2Y?? inhibitors were excluded. The CONUT score was calculated from serum albumin, total cholesterol, and lymphocyte count. The primary endpoint was 1-year MACE, defined as a composite of cardiovascular death, myocardial infarction, stroke, or unplanned revascularization. Results: MACE occurred in 72 patients (8.8%). Patients with MACE had higher age, hypertension, diabetes, and chronic kidney disease rates, and lower left ventricle ejection fraction (LVEF) and albumin levels (p<0.05). In the multivariate model, only lower LVEF (aOR 0.97; p = 0.030) and higher CONUT score (aOR 1.15; p = 0.049) remained independent predictors of MACE. Conclusion: The CONUT score independently predicts 1-year MACE in ACS patients receiving contemporary ticagrelor therapy. Incorporating nutritional assessment into routine risk stratification may guide intensified secondary prevention strategies.
